158 related articles for article (PubMed ID: 31403907)
1. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington.
Hood JE; Banta-Green CJ; Duchin JS; Breuner J; Dell W; Finegood B; Glick SN; Hamblin M; Holcomb S; Mosse D; Oliphant-Wells T; Shim MM
Subst Abus; 2020; 41(3):356-364. PubMed ID: 31403907
[No Abstract] [Full Text] [Related]
2. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.
Bachhuber MA; Thompson C; Prybylowski A; Benitez J; Mazzella S; Barclay D
Subst Abus; 2018; 39(2):167-172. PubMed ID: 29474119
[TBL] [Abstract][Full Text] [Related]
3. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
Carter J; Zevin B; Lum PJ
Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
[TBL] [Abstract][Full Text] [Related]
4. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.
Fox AD; Chamberlain A; Sohler NL; Frost T; Cunningham CO
J Subst Abuse Treat; 2015 Jan; 48(1):112-6. PubMed ID: 25205666
[TBL] [Abstract][Full Text] [Related]
5. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
Jakubowski A; Fowler S; Fox AD
Addict Sci Clin Pract; 2023 Jun; 18(1):40. PubMed ID: 37301953
[TBL] [Abstract][Full Text] [Related]
6. Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness.
Fine DR; Lewis E; Weinstock K; Wright J; Gaeta JM; Baggett TP
JAMA Netw Open; 2021 Mar; 4(3):e210477. PubMed ID: 33662132
[TBL] [Abstract][Full Text] [Related]
7. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic.
Doorley SL; Ho CJ; Echeverria E; Preston C; Ngo H; Kamal A; Cunningham CO
Subst Abus; 2017; 38(1):26-30. PubMed ID: 27897918
[TBL] [Abstract][Full Text] [Related]
9. Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.
Krawczyk N; Buresh M; Gordon MS; Blue TR; Fingerhood MI; Agus D
J Subst Abuse Treat; 2019 Aug; 103():1-8. PubMed ID: 31229187
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
11. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.
Stancliff S; Joseph H; Fong C; Furst T; Comer SD; Roux P
J Addict Dis; 2012; 31(3):278-87. PubMed ID: 22873189
[TBL] [Abstract][Full Text] [Related]
12. Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes.
Jakubowski A; Norton BL; Hayes BT; Gibson BE; Fitzsimmons C; Stern LS; Ramirez F; Guzman M; Spratt S; Marcus P; Fox AD
J Addict Med; 2022 Jul-Aug 01; 16(4):447-453. PubMed ID: 34775441
[TBL] [Abstract][Full Text] [Related]
13. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
[TBL] [Abstract][Full Text] [Related]
14. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.
Shah PA; Sohler NL; López C; Fox AD; Cunningham CO
J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine utilization among all Washington State residents' based upon prescription monitoring program data - Characteristics associated with two measures of retention and patterns of care over time.
Banta-Green CJ; Hansen RN; Ossiander EM; Wasserman CR; Merrill JO
J Subst Abuse Treat; 2021 Aug; 127():108446. PubMed ID: 34049724
[TBL] [Abstract][Full Text] [Related]
17. Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs.
Des Jarlais DC; Braine N; Friedmann P
AIDS Behav; 2007 Nov; 11(6 Suppl):78-84. PubMed ID: 17447132
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program.
Kaucher KA; Caruso EH; Sungar G; Gawenus L; Hurlbut K; Sanchez DC; Broderick K
Am J Emerg Med; 2020 Feb; 38(2):300-304. PubMed ID: 31387811
[TBL] [Abstract][Full Text] [Related]
19. "It's a place that gives me hope": A qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center.
Lai S; Li E; Silverio A; DeBates R; Kelly EL; Weinstein LC
Subst Abus; 2021; 42(4):858-864. PubMed ID: 33492204
[No Abstract] [Full Text] [Related]
20. Barriers to primary care physicians prescribing buprenorphine.
Hutchinson E; Catlin M; Andrilla CH; Baldwin LM; Rosenblatt RA
Ann Fam Med; 2014; 12(2):128-33. PubMed ID: 24615308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]